Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC

Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.

Datopotamab deruxtecan for the treatment of advanced non–small cell lung cancer is ongoing investigation in multiple clinical trials.

Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

Investigators reported the best objective response, progression-free survival, overall survival, and safety of a B7-H3–directed antibody-drug conjugate at the 2023 World Conference on Lung Cancer.

According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.